Catalog No.
MHC24206
Species reactivity
Human
Host species
Mouse
Isotype
IgG
Clonality
Monoclonal
Immunogen
Human free PSA/fPSA Protein.
Target
Prostate-specific antigen, PSA, 3.4.21.77, Gamma-seminoprotein, Seminin, Kallikrein-3, P-30 antigen, Semenogelase, KLK3, APS
Concentration
2.11 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Applications
ELISA, IFA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1A275
Design, characterization, and validation of a high-affinity synthetic peptide as bioreceptor for label-free detection of prostate specific antigen., PMID:40505236
PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer., PMID:40466338
High-Efficiency Detection of Total-PSA and Free-PSA in Whole Blood by Microfluidic Chip Integrated with Electromagnetic Co-Preprocessing., PMID:40456626
Polarity-Switchable Dual-Mode Photoelectrochemical Cancer Marker Immunoassay Based on a Metal-Organic Framework@Nitrogen-Doped Graphdiyne Heterojunction., PMID:40304230
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma., PMID:40145367
Gold Nanoparticle Incorporated Graphene Oxide as a SERS Platform for Ultratrace Antibody Free Sensing of the Cancer Biomarker CEA., PMID:40062598
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer., PMID:39964352
Label-free electrochemical immunoassay for ultra-sensitive detection of PSA utilizing gold nanoparticles/polyhedral hollow CoCu bimetallic sulfide nanostructure as a dual signal amplification platform., PMID:39884638
Effective Use of Euphorbia milii DCM Root Extract Encapsulated by Thermosensitive Immunoliposomes for Targeted Drug Delivery in Prostate Cancer Cells., PMID:39590308
Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer., PMID:39503807
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States., PMID:39352419
Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects., PMID:39330991
Platinum-perovskite nanocomposite-based Exosensor for specific detection of prostate cancer in clinical settings., PMID:39261334
Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D., PMID:38926066
Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States., PMID:38855109
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer., PMID:38838502
Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis., PMID:38811891
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial., PMID:38787530
Lectin-nanoparticle concept for free PSA glycovariant providing superior cancer specificity., PMID:38677453
Membrane-Free Lateral Flow Assay with the Active Control of Fluid Transport for Ultrasensitive Cardiac Biomarker Detection., PMID:38659215
Glycoprofiling of proteins as prostate cancer biomarkers: A multinational population study., PMID:38498504
A NiFe PBA/AuNPs nanocomposite sensitive immunosensor for electrochemical detection of PSA., PMID:38497295
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer., PMID:38430405
Phage Display's Prospects for Early Diagnosis of Prostate Cancer., PMID:38400052
Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer., PMID:38383374
Smartphone-Based Free-to-Total Prostate Specific Antigen Ratio Detection System Using a Colorimetric Reaction Integrated with Proximity-Induced Bio-Barcode and CRISPR/Cas12a Assay., PMID:38342699
Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials., PMID:38331400
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer., PMID:38300720
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial., PMID:38167882
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer., PMID:38101860
Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study., PMID:37940446
Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model., PMID:37736493
Investigating on sensing mechanism of MoS2-FET biosensors in response to proteins., PMID:37506679
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer., PMID:37386633
Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China., PMID:37313403
Electrochemical immunoassay for one-pot detection of thyroxin (T4) and thyroid-stimulating hormone (TSH) using magnetic and Janus nanoparticles., PMID:37254003
SERS-based biosensor for detection of f-PSA%: Implications for the diagnosis of prostate cancer., PMID:37196403
Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer., PMID:36918939
Shrink polymer based electrochemical sensor for point-of-care detection of prostate-specific antigen., PMID:36906988
Rational design of nonlinear hybridization immunosensor chain reactions for simultaneous ultrasensitive detection of two tumor marker proteins., PMID:36857646
A sensitive label-free biosensor based on Ag2S-sensitived Bi2WO6/BiOBr heterojunction for photoelectrochemical immunoassay of prostate specific antigen., PMID:36791596
Randomised phase II trial of stereotactic body radiotherapy in combination with checkpoint inhibitors in metastatic castration-resistant prostate cancer (CheckPRO): a study protocol., PMID:36717150
METCAM Is a Potential Biomarker for Predicting the Malignant Propensity of and as a Therapeutic Target for Prostate Cancer., PMID:36672713
Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms., PMID:36626706
Gold Nanoparticles-MWCNT Based Aptasensor for Early Diagnosis of Prostate Cancer., PMID:36551097
Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations., PMID:36455946
Kinetic Analysis of Prostate-Specific Antigen Interaction with Monoclonal Antibodies for Development of a Magnetic Immunoassay Based on Nontransparent Fiber Structures., PMID:36432177
Glucose oxidase-encapsulated liposomes for amplified autofluorescence-free immunoassay of a prostate-specific antigen with photoluminescence of CePO4:Tb nanocrystals., PMID:36416489
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial., PMID:36394849
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study., PMID:36289372
For research use only. Not for human or drug use.
